A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
Acromegaly is a disease characterized by excess growth hormone(GH) and insulin like growth
 factor(IGF)-1. Pituitary GH secreting adenoma is the major cause of acromegaly. Acromegalic
 cardiomyopathy is one of the leading causes of death in acromegalic patients. No efficient
 medicine is available for acromegalic cardiomyopathy until now and there were limited
 studies. Empagliflozin is proved to decrease the risk of heart failure in diabetic patients
 and independent of blood glucose control. We planed to evaluate the structure of heart by MRI
 before and after 6 months treatment with empagliflozin in acromegalic patients to investigate
 the effect of empagliflozin on acromegalic cardiomyopathy.
Inclusion Criteria:

 -  patients with pituitary GH adenomas confirmed by surgery

 active acromegalic patients although treated with surgery,radiation therapy and
 somatostatin analogs

 Exclusion Criteria:

 -  patients with contraindications to empagliflozin pregnant patients patients with poor
 control of hypertension(SBP>150mmHg or DBP>95mmHg patients with contraindications to
 MRI